Ashvattha Therapeutics, Inc.

Ashvattha Therapeutics, Inc.

is a clinical-stage biopharmaceutical company based in Redwood City, California. Founded in 2015, the company focuses on developing precision nanomedicines to address unmet medical needs in neurology, ophthalmology, hyperinflammatory diseases, and neuro-oncology. Ashvattha is recognized for its innovative platform that selectively targets and reprograms activated immune cells, such as macrophages and microglia, which play a role in various pathologies. The company's proprietary Hydroxyl Dendrimer (HD) platform enables the creation of Hydroxyl Dendrimer Therapeutics (HDTs) that can cross biological barriers and engage diseased tissues effectively. Ashvattha's product pipeline includes therapeutic candidates like OP-101 for inflammatory diseases, D-4517.2 for ophthalmological conditions, and OP-801, a diagnostic imaging agent for neuro-oncology. The company aims to improve treatment precision and reduce side effects for patients suffering from conditions like age-related macular degeneration, neurological disorders, and severe hyperinflammation.